Red blood cells covalently bound with two different polyethylene glycol derivatives

• US 6,312,685 B1
• Filed: 03/13/1998
• Issued: 11/06/2001
• Est. Priority Date: 03/13/1998
• Status: Expired due to Fees

• Current Assignee: Jonathan K. Armstrong, Timothy C. Fisher
• Original Assignee: Jonathan K. Armstrong, Timothy C. Fisher
• Inventors: Fisher, Timothy C., Armstrong, Jonathan K.
• Primary Examiner(s): Naff, David M.
• Application Number:
  US09/042,310
• Time in Patent Office: 1,334 Days
• Field of Search: 435/2, 435/174, 435/177, 435/180, 435/181, 435/325, 435/372, 424/93.7, 424/93.73, 530/385
• US Class Current: 424/93.7
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A01N 1/0221 Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
• CPC Class Codes: A61K 35/18 Erythrocytes haemoglobin A61K38/42

Abstract

Living cells are modified at their surface with specially selected polymers. Covalently attaching specially selected polyethylene glycol (PEG) derivatives to the surface of red blood cells (RBC) in aqueous media under mild conditions is a preferred example. The selected PEG derivatives dramatically reduced aggregation and low shear viscosity of RBC resuspended in autologous plasma, and inhibited RBC agglutination by blood group-specific antibodies. The morphology and deformability of the PEG-treated cells were unaltered. PEG coating of the RBC surface is applicable to the treatment of a variety of diseases characterized by vaso-occlusion or impaired blood flow, e.g., myocardial infarction, shock, and sickle cell disease. An infusion solution is prepared containing red blood cells covalently bound to a PEG derivative having a molecular weight of between 2,000 and 5,000 Daltons and a PEG derivative having a molecular weight between 10,000 and 35,000 Daltons.

Claims

1. A physiologically compatible solution for infusion comprising;

red blood cells covalently bound with at least two polyethylene glycol derivatives, wherein a first polyethylene glycol derivative has a molecular weight range of between 2,000 and 5,000 Daltons and wherein a second polyethylene glycol derivative has a molecular weight range of between 10,000 and 35,000 Daltons.

2. The physiologically compatible solution of claim 1 wherein the molecular weight of the second polyethylene glycol derivative is approximately 18,500.

3. The physiologically compatible solution of claim 1 wherein the molecular weight is of the first polyethylene glycol derivative is approximately 3,350.

4. The physiologically compatible solution of claim 1 wherein at least one of the first and second polyethylene glycol derivative is a monofunctional cyanuric chloride derivative.

5. The solution of claim 1 wherein at least one of the first and second polyethylene glycol derivative is a difinctional cyanuric chloride derivative.

6. A method to produce a physiologically compatible solution comprising;

covalently binding a first polyethylene glycol derivative to a population of red blood cells, wherein the first polyethylene glycol derivative has a molecular weight range of between approximately 2,000-5,000 Daltons, and

covalently binding a second polyethylene glycol derivative to the red blood cells, wherein the second polyethylene glycol derivative has a molecular weight range of between approximately 10,000-35,000 Daltons.

7. The method of claim 6 wherein the first polyethylene glycol derivative has a molecular weight of approximately 3,350.

8. The method of claim 6 wherein the second polyethylene glycol derivative has a molecular weight of approximately 18,500.

9. The method of claim 6 wherein the first or second polyethylene glycol derivative is a monofinctional cyanuric chloride derivative.

10. The method of claim 6 wherein the first or second polyethylene glycol derivative is a difunctional cyanuric chloride derivative.